The Schall Law Firm reminded investors of a securities class action against Ultragenyx Pharmaceutical, alleging the company misled investors about its osteogenesis imperfecta drug candidate. The complaint says Phase III ORBIT results failed to show a statistically significant drop in annualized fracture rate, rendering prior statements false and materially misleading. Investors who bought shares from August 3, 2023 to December 26, 2025 are urged to contact the firm before April 6, 2026. The class has not been certified; those taking no action remain absent members. The complaint says investors suffered damages when the market learned the truth.

Prepared by Christopher Adams and reviewed by editorial team.